scholarly journals The accuracy of an oscillometric ankle-brachial index in the diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis

2017 ◽  
Vol 71 (9) ◽  
pp. e12994 ◽  
Author(s):  
Ángel Herráiz-Adillo ◽  
Iván Cavero-Redondo ◽  
Celia Álvarez-Bueno ◽  
Vicente Martínez-Vizcaíno ◽  
Diana P. Pozuelo-Carrascosa ◽  
...  
Keyword(s):  
Systematic Review ◽  
Peripheral Arterial Disease ◽  
Lower Limb ◽  
Meta Analysis ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
Peripheral Arterial

scholarly journals The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis

2020 ◽  
Vol 315 ◽  
pp. 81-92
Author(s):  
Ángel Herraiz-Adillo ◽  
Iván Cavero-Redondo ◽  
Celia Álvarez-Bueno ◽  
Diana P. Pozuelo-Carrascosa ◽  
Montserrat Solera-Martínez
Keyword(s):  
Systematic Review ◽  
Peripheral Arterial Disease ◽  
Lower Limb ◽  
Meta Analysis ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
Toe Brachial Index ◽  
Peripheral Arterial

Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis

2014 ◽  
Vol 63 (2) ◽  
pp. 79-87 ◽  
Author(s):  
George A. Antoniou ◽  
Robert K. Fisher ◽  
George S. Georgiadis ◽  
Stavros A. Antoniou ◽  
Francesco Torella
Keyword(s):  
Systematic Review ◽  
Peripheral Arterial Disease ◽  
Statin Therapy ◽  
Lower Limb ◽  
Meta Analysis ◽  
Arterial Disease ◽  
Peripheral Arterial

Paradoxically lower prevalence of peripheral arterial disease in South Asians: a systematic review and meta-analysis

Heart ◽  
2013 ◽  
Vol 100 (2) ◽  
pp. 100-105 ◽  
Author(s):  
Meghan Sebastianski ◽  
Mark J Makowsky ◽  
Marlene Dorgan ◽  
Ross T Tsuyuki
Keyword(s):  
Systematic Review ◽  
Peripheral Arterial Disease ◽  
South Asians ◽  
Meta Analysis ◽  
Arterial Disease ◽  
Lower Prevalence ◽  
Peripheral Arterial

scholarly journals Meta-analysis on the safety and efficacy of Lumbrokinase in peripheral arterial disease

2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
A Agoncillo
Keyword(s):  
Peripheral Arterial Disease ◽  
Meta Analysis ◽  
Ankle Brachial Index ◽  
Drug Efficacy ◽  
Risk Groups ◽  
Arterial Disease ◽  
Duration Of Treatment ◽  
Standard Regimen ◽  
Safety And Efficacy ◽  
Peripheral Arterial

Abstract Funding Acknowledgements Type of funding sources: None. Background Lumbrokinase, an oral anti-thrombotic and fibrinolytic agent, was not yet part of the recommendations of any recommendations but had shown in two studies that it could increase the Ankle Brachial Index (ABI). ABI was used to evaluate the drug efficacy for PAD. Purpose Peripheral Arterial Disease was one of the most neglected, under-screened, and undertreated high-risk groups among cardiovascular diseases like myocardial infarction and stroke. Few studies were done to evaluate the treatment of fibrinolytic such as Lumbrokinase for this population.  Methods We appraised two randomized control trials that evaluated the safety and efficacy of Lumbrokinase compared to placebo with the standard regimen and another study of Lumbrokinase compared to placebo with standard regimen versus Lumbrokinase with Prostaglandin E1 (PGE1) among adult patients for the reduction of symptoms of PAD and increase in ABI. Both trials treatment period lasted for 2 weeks. Two independent reviewers assess the identified trials for inclusion by applying the selection criteria and quality was assessed using the JADAD scale. The data was analyzed using Meta analyst statistical software. Main results After weeks of treatment, the effect size is 0.90; this is an increase of at least +0.06 from the baseline that supports the trend in increasing the ankle-brachial index. The study did not show significant side effects by Lumbrokinase Conclusions Lumbrokinase at 460 to 490 mg three times a day for 2 weeks to 3 months has no significant relationship but has a trend in increasing the ankle-brachial index to a borderline level compared to placebo. Additional studies regarding the effect of Lumbrokinase in increasing ABI must be done with larger sample size.  Further research is needed to illuminate whether a longer duration of treatment with Lumbrokinase can increase the ankle-brachial index more. Eligible Trials Table 1. Eligible trials, characteristics, and demographics.AuthorYearControlPatient enrolled (N)Patient Analysed (%)Age Mean SDMales %Diabetes %Dyslipidemia %1. NDRAHA2013PlaceboL = 10 C= 10L = 100 C = 100L = 55.8 C = 53.2L = 5 C = 5L = 35 C = 25L = 30 C = 302. LUL= 31 C = 31L = 100 C = 100L = 68 C = 68.4L = 74 C = 74NANASUM/RAW MEANSL= 41 C = 41L = 100 C = 100L = 61.9 C = 60.8L = 39.4 C = 39.4NANAL= Lumbrokinase groupC= Control groupNA = not availableAbstract Figure. Efficacy of Lumbrokinase

Sign in / Sign up

Export Citation Format

Share Document